News

May 2019

press-releaseRegistration

The novel blood biomarker Copeptin is now available for clinical use in early rule-out of acute myocardial infarction and diagnosing water balance disorders

B·R·A·H·M·S Copeptin proAVP KRYPTOR has been registered in Canada allowing for faster, more reliable indirect measurement of vasopressin to improve diagnostic algorithms

Read the press release here >

 

May 2019

eventResearch

European Endocrinology Award 2019 for research about Copeptin

Prof. Christ-Crain gave a lecture on “New diagnostic approaches in the diagnosis of Diabetes insipidus” at the opening ceremony of the ECE 2019, because she received the European Endocrinology Award 2019 for her research about Copeptin.

Watch Award Lecture >

 

March 2019

publicationAdPKD

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).

Read the article in Kidney International >

Find more studies about Copeptin >

 

News Archive

thermo scientific applied biosystems invitrogen fisher scientific unity lab service